| Germline and somatic genetic landscape of pediatric myelodysplastic syndromes |
|
Haematologica |
Myelodysplastic Syndromes (MDS) |
| Characterization and Clinical Implications of p53 Dysfunction in Patients With Myelodysplastic Syndromes |
|
Journal of Clinical Oncology |
Myelodysplastic Syndromes (MDS) |
| Advances and challenges in the treatment of myelodysplastic syndromes |
|
Experimental Hematology & Oncology |
Myelodysplastic Syndromes (MDS) |
| Disease Burden at the Time of Transplantation Is a Primary Predictor of Outcomes in Pediatric MDS: A Single-Center Experience |
|
Cancers |
Myelodysplastic Syndromes (MDS), Pediatric |
| New Approvals in Low- and Intermediate-Risk Myelodysplastic Syndromes |
|
American Society of Clinical Oncology Educational Book |
Myelodysplastic Syndromes (MDS) |
| Infections in lower-risk myelodysplastic syndromes - prevalence and risk factors: a report from the European MDS Registry |
|
Haematologica |
Myelodysplastic Syndromes (MDS) |
| Oral decitabine cedazuridine with and without venetoclax in higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia: a propensity score-matched study |
|
Blood Cancer Journal |
Myelodysplastic Syndromes (MDS) |
| Sustained benefits of imetelstat on patient-reported fatigue in patients with lower-risk myelodysplastic syndromes ineligible for, or relapsed/refractory to, erythropoiesis-stimulating agents and high transfusion burden in the phase 3 IMerge study |
|
Leukemia & Lymphoma |
Myelodysplastic Syndromes (MDS) |
| Venetoclax and azacitidine in untreated patients with therapy-related acute myeloid leukemia, antecedent myelodysplastic syndromes or chronic myelomonocytic leukemia |
|
Blood Cancer Journal |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
| Advancing drug development in myelodysplastic syndromes |
|
Blood Advances |
Myelodysplastic Syndromes (MDS) |
